Peps
What is Dulaglutide?
Dulaglutide, marketed as Trulicity, is a long-acting GLP-1 receptor agonist used in type 2 diabetes care. Its research includes blood-sugar control and cardiovascular outcomes.
Biological role or research focus
Incretin signaling in type 2 diabetes care.
Evidence for a prescribed diabetes product is not evidence for an unverified research vial.
Role reference: MedlinePlus · Dulaglutide injection ↗
Names you may encounter
Trulicity
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class
- GLP-1 receptor agonist
- Brand
- Trulicity
- Form
- Once-weekly prescription injection
- Half-life
- Approximately 5 days
Source: FDA · Trulicity prescribing information · March 2026 ↗
Molecular structure
How dulaglutide works
Dulaglutide mimics an incretin signal. When blood glucose is elevated, it helps the pancreas release insulin; insulin allows tissues to take up glucose from the blood. It also slows stomach emptying and can reduce appetite. These actions connect its effects on glucose with the weight changes reported in some trials.
It is a diabetes-management medicine, not a cure. Medication, nutrition, activity, and monitoring remain parts of ongoing care. Its effects on blood sugar should be distinguished from evidence about clinical events such as heart attacks and strokes.
Approved uses in the United States
The March 2026 FDA label covers improved glucose control alongside diet and exercise in adults and children aged 10 and older with type 2 diabetes. It also covers reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
Weight management alone is not a listed indication. Approval belongs to the specified medicine and population; it does not extend to every product advertised with a peptide name.
Source: FDA · Trulicity prescribing information · March 2026 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2019
REWIND
Does treatment reduce cardiovascular events?
- Population / model
- 9,901 adults aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors.
- Study design
- Randomized, double-blind comparison with placebo added to existing care; median follow-up 5.4 years.
- Main finding
- The combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 12.0% with dulaglutide and 13.4% with placebo. Hazard ratio: 0.88 (95% confidence interval 0.79–0.99).
- How to read it
- The observed difference was 1.4 percentage points. The hazard ratio describes a 12% relative reduction in the event hazard, not a 12-percentage-point reduction in risk. All-cause mortality was not significantly different.
- Limits & context
- This was a cardiovascular-risk population with diabetes. The results do not establish a longevity benefit in healthy people. Gastrointestinal events were more frequent with dulaglutide.
Human randomized trial · 2021
AWARD-11
How did higher studied doses compare for glucose and weight?
- Population / model
- 1,842 adults with type 2 diabetes inadequately controlled with metformin; mean starting HbA1c 8.6%.
- Study design
- Randomized 52-week trial comparing three dulaglutide dose groups; primary comparison at 36 weeks.
- Main finding
- In the analysis including treatment discontinuation or rescue medication, HbA1c fell 1.77 percentage points in the 4.5-mg group versus 1.54 in the 1.5-mg group. Weight fell 4.6 kg versus 3.0 kg.
- How to read it
- The 4.5-mg group had greater average reductions. The 3.0-mg group did not meet superiority over 1.5 mg for HbA1c in that analysis, although it did in the on-treatment analysis.
- Limits & context
- The comparator was another dulaglutide dose, not placebo or a different medicine. These are trial groups, not personal dosing instructions. Weight results in metformin-treated diabetes cannot simply be transferred to people without diabetes.
Human randomized trial · 2022
AWARD-PEDS
What was found in younger people with type 2 diabetes?
- Population / model
- 154 participants aged 10 to under 18 with type 2 diabetes and BMI above the 85th percentile.
- Study design
- Double-blind, placebo-controlled trial with a 26-week primary comparison, followed by an open-label extension.
- Main finding
- HbA1c rose 0.6 percentage points with placebo and fell 0.6 and 0.9 points in the two dulaglutide groups. HbA1c below 7% was reached by 51% of the pooled dulaglutide groups versus 14% with placebo.
- How to read it
- Glucose control improved, but the groups did not differ in BMI change. A glucose-lowering result and a weight-loss result are different findings.
- Limits & context
- The study does not establish treatment for obesity alone, children under 10, or long-term cardiovascular outcomes in youth.
These trials were sponsored by Eli Lilly. Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Important label warnings
The boxed warning concerns thyroid C-cell tumors in rodents; human relevance is unknown. Personal or family medullary thyroid carcinoma, MEN 2, and serious hypersensitivity are contraindications. Other warnings include pancreatitis, dehydration-related kidney injury, severe gastrointestinal reactions, retinopathy complications, gallbladder disease, and aspiration during anesthesia. Insulin or sulfonylureas can increase hypoglycemia risk. See the complete label.
Source: FDA · Trulicity prescribing information · March 2026 ↗
Patient information
Reported side effects include nausea, diarrhea, heartburn, reduced appetite, and tiredness. Review other medicines, pregnancy or breastfeeding, and planned procedures with the care team. Persistent severe abdominal pain, breathing difficulty, or face/throat swelling require urgent medical attention.
Source: MedlinePlus · Dulaglutide injection ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
2 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Biohackingturkey
Dulaglutide Nedir? 45 Saniyede Diyabet Peptidi ↗
Title match · Captions not indexed
Biohackingturkey
Dulaglutide Nedir? Zayıflama ve Diyabetteki Mucize Peptit! ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Evidence for a prescribed diabetes product is not evidence for an unverified research vial.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does an improvement in HbA1c prove fewer heart attacks?
No. A laboratory outcome and a clinical event answer different questions. AWARD-11 examined glucose and weight; REWIND directly studied cardiovascular events. Read the endpoint before interpreting a headline.
Does “weight loss in a study” mean it is an obesity medicine?
No. The trial population and approved indication both matter. AWARD-11 observed weight changes in adults with diabetes taking metformin; that is not a study of treatment for obesity alone.
Have all dulaglutide studies been reviewed here?
No. This profile summarizes a current US label, patient information, and three selected trial abstracts. It is not a systematic review or an independently medically reviewed prescribing reference. Additional populations, comparisons, and longer-term follow-up may change the picture.
References & editorial record
- MedlinePlus · Dulaglutide ↗
- FDA · Trulicity prescribing information · March 2026 ↗
- REWIND · Gerstein et al. · The Lancet, 2019 ↗
- AWARD-11 · Frias et al. · Diabetes Care, 2021 ↗
- AWARD-PEDS · Arslanian et al. · NEJM, 2022 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.